Evidence map›Paper›PMID 41409805›Full record

ReviewJournal of rheumatic diseases2026

Review of literature: posterior reversible encephalopathy syndrome in systemic lupus erythematosus.

Farah Jaafar Mahdi

Abstract readReview
In one paragraph

Review in Journal of rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Farah Jaafar MahdiDivision of Rheumatology, Department of Internal Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.ORCID https://orcid.org/0009-0004-1577-6933

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a neuroradiological disorder primarily affecting the posterior circulation of the brain. It manifests with a spectrum of symptoms, typically accompanied by hypertension, headache, seizures, and blurred vision. The etiology of PRES remains uncertain, but it is believed to be associated with vasogenic edema. The underlying conditions can range from sepsis to drug-induced states, autoimmune diseases, systemic lupus erythematosus (SLE), which is the most prevalent connective tissue disease associated with PRES. SLE is a multisystemic disorder that impacts various organs in the body, with musculoskeletal and skin systems being the most affected. The morbidity and mortality associated with SLE stem from its potential involvement of life-threatening organs, including the central nervous system, kidneys, and respiratory system. This article will focus on the neurological impact of PRES, including its manifestations. The association between PRES and SLE will be discussed in detail, accompanied by a literature review that explores the variability of presentation, reversibility, and prognosis.

Indexed as

Posterior reversible encephalopathy syndromeSeizureSystemic lupus erythematosus

Identifiers

PMID41409805
PMCPMC12706435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.